ASCENTAGE PHARMA GROUP INTERNATIONAL
Business
ASCENTAGE PHARMA GROUP INTERNATIONAL is a global, integrated biopharmaceutical company that discovers, develops and commercializes small‑molecule therapies primarily targeting hematological malignancies. Its main products and candidates include lead assets olverembatinib and lisaftoclax, alongside clinical‑stage programs such as alrizomadlin, pelcitoclax, APG‑2449 and APG‑5918, supported by a proprietary drug discovery and degrader platform. The company operates R&D, clinical development, manufacturing and commercialization activities and maintains collaborations and licensing arrangements. It conducts clinical trials and commercializes products across China, the United States, Australia, Europe, Canada and other international markets.
Summary from filing dated 2025-04-16
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-177.75M |
| Total assets | — |
| Total liabilities | $375.99M |
| Stockholders' equity | — |
| Operating cash flow | — |